Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556629 · ClinicalTrials.gov registry record
A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA
A clinical trial, sponsored by Shire.
- Completed
- Registry status
- 200
- Enrollment target
NCT05556629: Completed study, sponsored by Shire.
NCT05556629 is a clinical trial that has completed, run by Shire. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05556629 has completed, sponsored by Shire.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This main aim of this study is to check the level of knowledge and assess attitudes and behaviors of both participants and prescribing physicians regarding the risks and safe use of NATPARA. The survey will be done via internet, telephone, or paper and participants will be able to choose the method that is preferred. No study medicines will be provided to patients in this study.
Primary Outcome
All question for key risk message and about NATPARA will be asked through a questionnaire, Participant or prescribing physicians (HCPs) would need to respond true or false to each question based upon understanding and knowledge. Respondents could be participants or HCPs.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-09-01 |
| Est. Completion | 2025-11-30 |
What the finished NCT05556629 record still lists
NCT05556629 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05556629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05556629 about?
NCT05556629 is a clinical study titled "A Survey to Assess Participants' and Physicians' Knowledge, Attitudes and Behavior When Using NATPARA". This main aim of this study is to check the level of knowledge and assess attitudes and behaviors of both participants and prescribing physicians regarding the risks and safe use of NATPARA. The survey will be done via internet, telephone, or paper and participants will be able to choose the method ...
What is the current status of trial NCT05556629?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2015-09-01. Estimated completion is 2025-11-30.
What interventions are being tested in trial NCT05556629?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05556629?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI